BUY MBP IBRUTINIB IBRUNAT 140MG 30CAP BEST PRICE ONLINE IN NIGERIA LAGOS ABUJA KANO AND PORTHARCOURT AT MYBIGPHARMACY.COM

Description

Dear friend, this medication requires a prescription or medical license before it can be delivered to you. kindly ensure that you provide us with a reliable contact information at checkout, mybigpharmacy team will be in touch with you to obtain required document before your order is confirmed thank you for trusting mybig pharmacy with your health. Ibrutinib is an oral anticancer medicine used to treat several types of blood cancers, particularly those affecting B lymphocytes. It is commonly prescribed for conditions such as chronic lymphocytic leukaemia, small lymphocytic lymphoma, mantle cell lymphoma, Waldenstr?m?s macroglobulinaemia, and certain other B-cell malignancies. Ibrutinib belongs to a class of medicines known as Bruton?s tyrosine kinase inhibitors, often referred to as BTK inhibitors.

Ibrutinib works by blocking an enzyme called Bruton?s tyrosine kinase, which plays a key role in the survival, growth, and spread of B cells. In cancerous B cells, this enzyme is overactive and helps the cancer cells survive longer than they should. By blocking this enzyme, ibrutinib disrupts signals that keep cancer cells alive, causing them to stop growing and eventually die. This targeted approach allows ibrutinib to treat cancer more selectively than traditional chemotherapy.

Ibrutinib is taken by mouth once daily, usually at the same time each day, with a full glass of water. It can be taken with or without food, but it should be taken consistently in the same way each day. Capsules or tablets should be swallowed whole and not crushed, opened, or chewed. Treatment with ibrutinib is typically long term and continues as long as the disease is controlled and side effects remain manageable.

During the early phase of treatment, some patients may notice a temporary increase in lymph node size or white blood cell counts. This is a known effect of ibrutinib and usually does not mean the disease is getting worse. It happens because cancer cells are being pushed out of lymph nodes into the bloodstream before they are eliminated.

Common side effects of ibrutinib include diarrhoea, fatigue, nausea, muscle or joint pain, bruising, rash, and mild infections such as colds or sinus infections. These side effects are often mild to moderate and may improve over time. Staying hydrated and reporting symptoms early can help manage side effects effectively.

Ibrutinib can increase the risk of bleeding because it affects platelet function. Patients may notice easy bruising, nosebleeds, or bleeding gums. Serious bleeding is less common but can occur, especially in people taking blood thinners or those undergoing surgery. Patients should inform healthcare providers of any planned procedures and avoid medications such as aspirin or non-steroidal anti-inflammatory drugs unless approved by their doctor.

Another important side effect of ibrutinib is an increased risk of heart rhythm problems, particularly atrial fibrillation. Symptoms may include palpitations, shortness of breath, dizziness, or chest discomfort. Patients with a history of heart disease should be closely monitored, and any new heart symptoms should be reported immediately.

Ibrutinib can also increase the risk of infections, including serious bacterial, viral, or fungal infections. Because it affects immune function, patients should promptly report fever, chills, cough, or other signs of infection. Vaccinations with live vaccines should be avoided during treatment.

Drug interactions are common with ibrutinib. Certain antibiotics, antifungals, antiviral medicines, and herbal supplements such as St John?s wort can affect how ibrutinib is processed in the body. Grapefruit and Seville oranges should be avoided, as they can increase drug levels and raise the risk of side effects.

Ibrutinib is not recommended during pregnancy or breastfeeding, as it may harm the unborn baby or infant. Effective contraception is advised during treatment and for a period after stopping therapy.

Regular follow-up is essential while taking ibrutinib. Blood tests are used to monitor blood counts, liver function, and overall response to treatment. Dose adjustments may be needed if side effects occur.

Although ibrutinib does not cure blood cancers, it has significantly improved outcomes for many patients by controlling disease progression, reducing symptoms, and improving quality of life. When taken consistently and monitored carefully, ibrutinib can provide long-term disease control for many individuals with B-cell malignancies.